Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Verona Pharma to Present at Upcoming Healthcare Investor Conferences

Verona Pharma plc
Posted on: 15 Mar 18

LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company management will present at three upcoming investor conferences:

Event: 28th Annual Oppenheimer Healthcare Conference
Date: March 21, 2018
Time: 3:55 PM EDT
Location: New York, NY

Event: Needham & Co. Annual Healthcare Conference
Date: March 27, 2018
Time: 12:15 PM EDT
Location: New York, NY

Event: H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2018
Time: 2:35 PM CEST
Location: Monte Carlo, Monaco

About Verona Pharma plc  
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc            
Jan-Anders Karlsson, Chief Executive Officer             
Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com 

FTI Consulting (UK Media and Investor enquiries)
Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com 

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire
HUG#2176622
GlobeNewswire
globenewswire.com

Last updated on: 16/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.